ArticlePLoS neglected tropical diseases2026
Time trends in the burden of scabies from 1990 to 2021, and projections to 2050: Insights based on the Global Burden of Disease Study 2021.
Article in PLoS neglected tropical diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundScabies is a parasitic skin disease known since ancient times, yet it remains a persistent and significant global health challenge in the modern era affecting populations around the world. This study aims to assess the global burden of scabies across all age groups from 1990 to 2021 and predict epidemiological trends up to 2050.
methodsThe study utilized data from the Global Burden of Disease Study 2021. Data from 204 countries and territories were stratified by sociodemographic index, gender, age. Age-standardized rates per 100,000 population were calculated for prevalence, incidence, and disability-adjusted life years, with 95% uncertainty intervals. Trends were assessed using Joinpoint regression models to compute the annual percent change. A time-series analysis-based prediction model was applied to estimate age-standardized incidence rates up to 2050.
findingsIn 2021, the global incidence and prevalence of scabies in both sexes were 622.4 million (95% UI 556.2-695) and 206.5 million (95%UI 184.1-231.7) respectively. The age-standardized prevalence rate was 2666.47 per 100,000 population (95% UI: 2368.2-2994.5), and the age-standardized incidence rate was 8049.53 per 100,000 (95% UI: 7165.24-9024.24). The disability-adjusted life years reached 68.72 per 100,000 (95% UI: 38.3-113.2). Joinpoint regression analysis indicated a modest downward trend in age-standardized prevalence rate that did not reach statistical significance (p = 0.411), suggesting limited evidence for global improvement in scabies control. Age-stratified analysis revealed a distinct bimodal age distribution pattern in scabies incidence, the first at ages 5-14 and the second at 20-24, declining after age 25. Frontier analysis demonstrated that middle sociodemographic index regions carried the heaviest scabies burden, with the highest incidence and prevalence rates worldwide. According to the Auto-Regressive Integrated Moving Average time-series model, the global age-standardized incidence rate of scabies is predicted to decline overall by 2050, and these findings indicate that future trends are expected to vary substantially by region.
conclusionsScabies remains a severe public health problem worldwide, and its incidence and disease burden demonstrate significant regional and age-related variations. The age-standardized prevalence rate in most sociodemographic index regions showed a downward trend, reflecting that the incidence of scabies has been controlled to some extent, but the prevalence rate is still very high. However, the future epidemiological trend of scabies has regional heterogeneity, public health interventions should focus on countries and territories in the high-middle sociodemographic index regions and middle sociodemographic index regions, optimizing healthcare resource allocation, improving basic health infrastructure, enhancing health education.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.